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1. INTRODUCTION
The discovery nearly 30 years ago that v-src (the form
of the Src kinase encoded by Rous sarcoma virus)
employs tyrosine kinase activity for transforming cells
led, decades later, to a revolution in molecular medi-
cine. The identification of key signalling pathways
controlled by this reversible phosphorylation opened
a new means by which cell machinery could be acti-
vated or inhibited. As these signalling pathways were
discovered to contribute in multiple ways to the on-
cogenic process, tyrosine kinases became key targets
for clinical interventions. Today, it is routine to see
cancer treatment regimens that include the use of ki-
nase inhibitors such as anti-receptor antibodies or
small molecules. Some examples include Herceptin
(Genentech, San Francisco, CA, U.S.A.), Gleevec
(Novartis Pharmaceuticals, St. Louis, MO, U.S.A.),
Iressa (AstraZeneca Pharmaceuticals, Wilmington,
DE, U.S.A.), and Tarceva (Genentech) 1–4.
Interestingly, it took more than 10 years after rec-
ognition of the protein-tyrosine kinases (PTKs) for the
first member of the family of protein-tyrosine phos-
phatases (PTPs) to be identified 5. The fact that the PTPs
have no structural similarity to serine threonine phos-
phatase may have contributed to the difficulties en-
countered in cloning those enzymes.
Because the PTPs perform enzymatic reactions that
are the reverse of those performed by the PTKs, the
PTPs were assumed to be tumour suppressors. En-
zymes such as PTEN that counteract the activation of
phosphoinositide-3-kinase (PI3K) are an excellent
example of such functioning by a PTP 6. However,
more recently, several findings have acknowledged
that, in many circumstances, members of the PTP
superfamily act as typical oncogenes 7. Recent ad-
vances in the generation of PTP inhibitors and posi-
tive outcomes in clinical trials of PTPN1 (protein
tyrosine phosphatase, non-receptor type 1; formerly
PTP1B) antisense for treatment of type 2 diabetes may
soon lead to the use of PTPs as markers and novel
targets in oncology.
In the present paper, we comment on the diver-
sity of the PTP superfamily, describe three of the main
members that are candidates with the most interest-
ing potential for cancer treatments, and briefly sur-
vey the major hurdle standing in the way of the
development of small-molecule PTP inhibitors for
clinical applications.
2. THE PTP SUPERFAMILY
Reversible tyrosine phosphorylation regulates many
cellular functions, including cell proliferation, sur-
vival, adhesion, and migration 8. In contrast to the
PTKs, which phosphorylate their substrates on tyrosine
residues, members of the PTP family remove phos-
phate from protein and from phospholipid substrates.
The  PTPs are now recognized to constitute a large,
structurally diverse family of tightly regulated en-
zymes with important regulatory roles 8. Recently,
Alonso et al. 9 identified a total of 107 PTPs encoded
in the human genome. This superfamily of PTPs can
be divided into four major enzyme subfamilies. En-
zymes from three of those families (classes I–III) con-
tain a catalytic oxidation-sensitive active cysteine
residue embedded within a conserved signature mo-
tif (XHCSXGXGRXG), which carries out catalysis
by executing a nucleophilic attack on its phospho
substrate 10.
Class I is the largest PTP subfamily, comprising
the 38 classical PTPs and 61 dual-specificity phos-
phatases. Classical PTPs show specificity for phospho-
tyrosine, and the dual-specificity phosphatases can
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dephosphorylate phosphotyrosine-, phosphoserine-,
and phosphothreonine-containing substrates. Among
the class I members, PTEN and the myotubularin sub-
family are the enzymes that preferentially target phos-
pholipids. Class II has a single member, the so-called
low molecular weight PTP (LM-PTP), and class III en-
compasses the three mammalian Cdc25 proteins,
which participate in cell-cycle regulation. Class IV is
a newly identified aspartate-based PTP family related
to the Eya family.
2.1 PTEN: A KEY TUMOUR SUPPRESSOR IN
CANCERS
The PTEN (phosphatase and tensin homologue) gene
on chromosome 10q23.31, also known as MMAC1
(mutated in multiple advanced cancers), encodes a
tumour-suppressor protein that acts as an inhibitor
of the PI3K-AKT pathway. By removing the 3¢ phos-
phate group of phosphatidylinositol-(3,4,5)-triphos-
phate, PTEN counteracts the activity of PI3K in
promoting cellular growth, survival, and angiogen-
esis 6. Mutations in PTEN are responsible for Cowden
syndrome and other autosomal dominant disorders
such as Bannayan–Riley–Ruvacalba syndrome and
the Proteus and Proteus-like syndromes 11.
Apart from its role in hereditary syndromes, PTEN
inactivation has been identified in a series of spo-
radic human cancers, including glioblastomas of the
central nervous system, endometrial carcinoma, pro-
static adenocarcinoma, and melanoma 12,13. Interest-
ingly, some of the PTEN mutations may lead to
protein instability and rapid removal through protein
ubiquitination 14. As a therapeutic strategy for PTEN-
related cancer, it may perhaps be possible to target
the specific ubiquitin ligase involved in that process,
thus blocking PTEN degradation and maintaining, or
restoring, some phosphatase activity that could pre-
vent AKT pathway activation.
2.2 Shp2 and Leukemias
Shp2 is encoded by the PTPN11 gene in humans. It
transduces mitogenic and pro-migratory signals from
various receptor types via activation of the ras/ERK
cascade 15.
Somatic mutations of PTPN11 are the major cause
of sporadic juvenile myelomonocytic leukemia, ac-
counting for about 35% of cases 16. In addition, mu-
tations of this gene also occur in approximately 6%
of patients with childhood acute lymphoblastic leu-
kemia 17 and in 4%–5% of patients with acute my-
eloid leukemia 18. Mutations of PTPN11 are
uncommon in solid human tumours, but they have
been detected in neuroblastoma, melanoma, lung
adenocarcinomas, and colon cancer 18.
Most of the mutations in the PTPN11 gene lead
to expression of Shp2 variants with single amino-
acid changes that enhance the protein’s activity. In
addition to its well-established pro-oncogenic poten-
tial in various types of leukemia, Shp2 is also a key
downstream target of other oncogenes shown to drive
excessive mammary epithelial cell proliferation and
a potentiator of neu-induced transformation in mouse
models 19,20. Inhibiting Shp2 thus offers several new
therapeutic avenues in several types of cancer.
2.3 PTPN1: A Surprising Oncogene
As the prototype for the superfamily of PTPs, PTPN1
has been implicated in multiple signalling pathways,
including pathways triggered by growth factors, hor-
mones, and cytokines 21. Because it is a negative regu-
lator of oncogenic tyrosine kinase receptors such as
the insulin receptor and insulin-like growth factor 1
receptor, PTPN1 was first thought to be a tumour sup-
pressor. Yet surprisingly, PTPN1 knockout mice do
not develop cancers.
Interestingly, PTPN1 is located within 20q13, a
region frequently amplified in ovarian and breast
cancers and usually associated with a poor progno-
sis 22. Immunocytochemical studies have shown that
PTPN1 is overexpressed in 40% of human breast
cancers 23,24, and furthermore, PTPN1 has been shown
to be able to activate the oncogene src 25 and has been
reported to have a positive role in the ras pathway 26.
Recently, our group and Dr. Benjamin Neel’s
laboratory demonstrated that deletion of PTPN1 ac-
tivity in MMTV-neu transgenic mice by breeding with
PTPN1-deficient mice caused significant mammary
tumour latency and resistance to lung metastasis 27,28.
Our group also used a specific PTPN1 inhibitor that
protected the MMTV-neu transgenic mice from devel-
oping tumours to confirm those findings 27. The lat-
ter study also demonstrated that PTPN1 is a true
oncogene, because specific overexpression of PTPN1
in the mammary gland led to the development of spon-
taneous breast cancer 27. Therefore PTPN1, previ-
ously recognized for its role in downregulating insulin
signalling, has now been shown to function as a posi-
tive regulator of signalling events associated with
breast tumorigenesis.
3. PHARMACOLOGIC TREATMENT OF
PTPN1
Several years ago, our group, in collaboration with
Brian Kennedy of Merck–Frosst, confirmed that
PTPN1 inhibition could have a significant benefit in
type 2 diabetes 29. That finding triggered much re-
search into the development of small molecules
against PTPN1.
Unfortunately, the close similarities between the
various members of the PTP family and the general
hydrophilicity of small molecules that bind to the PTP
active pocket remain major hurdles in the develop-
ment of specific inhibitors against PTPN1. It appears
that the PTP field has now reached the stage occupiedHARDY and TREMBLAY
7
CURRENT ONCOLOGY—VOLUME 15, NUMBER 1
by the kinase drug development field more than
10 years ago. For example, Isis Pharmaceuticals de-
veloped and, in late phase II clinical trials, success-
fully employed PTPN1 antisense inhibitors for the
treatment of type 2 diabetes 30. Their study clearly
validates PTPN1 as a safe target in humans. In that
context, the race for small-molecule inhibitors will
certainly gain momentum. Other companies should
soon emerge with their own versions of anti-PTPN1
small drugs. It stands to reason that these inhibitors
should rapidly be tested in cancers in which PTPN1
is overexpressed.
4. SUMMARY
It is now clear that PTPs have both inhibitory and
stimulatory effects on cancer-associated signalling
processes, and depending on their associated proteins
and substrates, they act as oncogenes in multiple
human cancers. Soon, several ongoing studies should
validate PTPs such as PTEN and PTPN1 as useful prog-
nostic markers and potentially novel targets in can-
cer therapies.
Although much current interest surrounds the
clinical introduction of specific PTK inhibitors, chemi-
cal targeting of PTPs remains largely unexplored. De-
spite major efforts by the pharmaceutical industry
(given that these targets were identified more than
10 years after the tyrosine kinases), the development
of small-molecule inhibitors of PTPs is still in its early
stages. Phosphatases represent 4% of the “drug-able”
human genome 31, and the rapidly increasing num-
ber of human diseases associated with PTP abnormali-
ties—including cancer—has begun to elicit a growing
interest in PTPs as drug targets in oncology. The re-
cent identification of PTPN1 as a potential oncogene
in breast cancer may be key in focusing research ef-
forts toward this relatively poorly known gene family.
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